HER2-Negative Breast Cancer Terminated Phase 2 Trials for Everolimus (DB01590)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02273752Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTreatment